Bronnen:
- Gandhi NM1, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int. 2013;112:288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Epub 2013 Mar 20.,Chen DS1, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. doi: 10.1016/j.immuni.2013.07.012.,Khan H, Gucalp R, Shapira I. Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol. 2015;2015:847383. doi: 10.1155/2015/847383. Epub 2015 Apr 28.,Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112:1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9.,Babjuk M, Böhle A, Burger M, et al. Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf (consulted 08.11.2015),Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.,Houghton BB, Chalasani V, Hayne D, et al. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int. 2013;111:977-83. doi: 10.1111/j.1464-410X.2012.11390.x. Epub 2012 Dec 17.,Astram A, Khadijah A, Yuri P, et al. Effective dose and adverse effects of maintenance Bacillus Calmette-Gue'Rin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial. Acta Med Indones. 2014;46:298-307.,Bijsluiter BCG. http://www.bcfi.be/GGR/Index.cfm?ggrWelk=/nIndex/GGR/Merk/MP_B.cfm (geconsulteerd 08.11.2015),Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-8. doi: 10.1038/nature12213. Epub 2013 Jun 16.,Gupta S, Gill D, Poole A, Agarwal N. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers (Basel). 2017;9(2). pii: E15. doi: 10.3390/cancers9020015. Review.